Clinical Trials: Hematologic Oncology

UNC Lineberger is participating in a novel lymphoma study at Virginia Commonwealth University Massey Cancer Center through the National Cancer Institute Southeast Phase II Consortium.

The phase II trial is a clinical study for certain sub-types of non-Hodgkin's lymphoma and is intended for patients whose disease has progressed following treatment with other regimens.

Kristy Richards, MD, PhD, (pictured above) is the primary investigator for the UNC based part of the trial. Read more about trial.

A partial list of priority hematologic cancer trials at UNC follows below.

NCI 8064: Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas (highlighted above)

PI: Kristy Richards, MD, PhD, 919-966-0374

Study Coordinator: Jennifer Whitman, RN, 919-843-7146, (toll free) 1-877-668-0683

LCCC 0715: A Phase I Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinza) in Patients with Relapsed/Refractory Multiple Myeloma (highlighted on right)

PI: Peter Voorhees, MD, 919-966-5879

Study Coordinator: Rey Garcia, RN, 919-843-3875, (toll free) 1-877-668-0683

LCCC 0708: A randomized dose-escalation of clofarabine in combination with gemtuzumab ozogamicin for relapsed/refractory Acute Myeloid Leukemia (AML) for patients less than 60 years-old

PI:  Tom Shea, MD, 919-966-7746

Study Coordinator: Jennifer Whitman, RN, 919-843-7146, (toll free) 1-877-668-0683

EM-1421-105: Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dependent-Kinase-1 (Cdc2) Inhibitor, in Patients with Leukemia or MDS

PI:  Tom Shea, MD, 919-966-7746

Study Coordinator: Rey Garcia, RN, 919-843-3875, (toll free) 1-877-668-0683

C14003: An Open-Label, Phase I Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies

PI:  Tom Shea, MD, 919-966-7746

Study Coordinator: Jennifer Whitman, RN, 919-843-3875, (toll free) 1-877-668-0683

UNC Hematologic Oncology Program

Pat Gerrick (pictured left along with her doctor, Tom Shea, MD) participated in an UNC clinical trial for acute leukemia and then received a bone marrow transplant as part of the trial.

Pat says: "I participated in the clinical trial because of the seriousness of my illness. I wanted to attack it with all available resources. I also wanted to participate in the process of trying to find a way to cure or control this disease."

Thankful for the care she received at UNC, Pat now serves on the UNC Lineberger Board of Visitors.

Read more about Pat Gerrick